Co-expression of a Ca2+-inhibitable Adenylyl Cyclase and of a Ca2+-sensing Receptor in the Cortical Thick Ascending Limb Cell of the Rat Kidney
INHIBITION OF HORMONE-DEPENDENT cAMP ACCUMULATION BY EXTRACELLULAR Ca2+*

Marie Céleste de Jesus FerreiraDagger , Cécile Héliès-Toussaint§, Martine Imbert-Teboul, Claire Bailly, Jean-Marc Verbavatz, Anne-Christine Bellanger, and Danielle Chabardès

From the Service de Biologie Cellulaire, Département de Biologie Cellulaire et Moléculaire, CEA Saclay, France

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The Ca2+-sensing receptor protein and the Ca2+-inhibitable type 6 adenylyl cyclase mRNA are present in a defined segment of the rat renal tubule leading to the hypothesis of their possible functional co-expression in a same cell and thus to a possible inhibition of cAMP content by extracellular Ca2+. By using microdissected segments, we compared the properties of regulation of extracellular Ca2+-mediated activation of Ca2+ receptor to those elicited by prostaglandin E2 and angiotensin II. The three agents inhibited a common pool of hormone-stimulated cAMP content by different mechanisms as follows. (i) Extracellular Ca2+, coupled to phospholipase C activation via a pertussis toxin-insensitive G protein, induced a dose-dependent inhibition of cAMP content (1.25 mM Ca2+ eliciting 50% inhibition) resulting from both stimulation of cAMP hydrolysis and inhibition of cAMP synthesis; this latter effect was mediated by capacitive Ca2+ influx as well as release of intracellular Ca2+. (ii) Angiotensin II, coupled to the same transduction pathway, also decreased cAMP content; however, its inhibitory effect on cAMP was mainly accounted for by an increase of cAMP hydrolysis, although angiotensin II and extracellular Ca2+ can induce comparable release of intracellular Ca2+. (iii) Prostaglandin E2, coupled to pertussis toxin-sensitive G protein, inhibited the same pool of adenylyl cyclase units as extracellular Ca2+ but by a different mechanism. The functional properties of the adenylyl cyclase were similar to those described for type 6. The results establish that the co-expression of a Ca2+-inhibitable adenylyl cyclase and of a Ca2+-sensing receptor in a same cell allows an inhibition of cAMP accumulation by physiological concentrations of extracellular Ca2+.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

A new type of G protein-coupled membrane receptor that is activated by increasing concentrations of extracellular ionized calcium ([Ca2+]e)1 and polyvalent cations has been cloned recently from bovine parathyroid cells (BoPCaR1, Ref. 1) and rat kidney (RaKCaR, Ref. 2). When expressed in Xenopus oocytes, these Ca2+-sensing receptors are coupled to phospholipase C stimulation (1, 2). Increasing [Ca2+]e also stimulates phospholipase C activity in parathyroid cells (3, 4) and inhibits hormone-dependent cAMP accumulation (5), but, so far, no interaction between these two transduction pathways has been established. The presence of BoPCaR1 in parathyroid cells explains the crucial role of [Ca2+]e to elicit a negative feedback on parathyroid hormone secretion (6, 7). In rat kidney, a predominant expression of RaKCaR mRNA has been localized in the cortical portion of the thick ascending limb (8, 9), a segment which ensures cAMP-stimulated paracellular Ca2+ reabsorption, from the lumen of the renal tubule to the extracellular fluid compartments (10). A functional Ca2+ receptor is expressed in the plasma membrane of the rat and mouse cortical thick ascending limb (CTAL) as evidenced by the properties of the dose-dependent increase in the concentration of intracellular calcium ([Ca2+]i) as a function of peritubular [Ca2+]e (11, 12). High [Ca2+]e (5 mM) in the mouse CTAL decreases hormone-dependent cAMP accumulation, an effect which has been ascribed to a direct inhibition of adenylyl cyclase (AC) activity (13).

Experiments using quantitative reverse transcription-polymerase chain reaction (RT-PCR) have shown that the rat CTAL also expresses the Ca2+-inhibitable type 6 AC mRNA (14). All the Galpha s-coupled receptors studied so far in this segment activate a single pool of AC catalytic units (15, 16), and in addition, electron microscopy studies describe a single cell type in this epithelium (17). These observations lead to the hypothesis that the functional expression of the type 6 AC mRNA accounts for the hormone-dependent cAMP synthesis in the rat CTAL.

The aim of the present study was therefore to investigate the functional expression of the AC present in the rat CTAL and the consequences of the possible co-localization in a same cell of a Ca2+-inhibitable AC and of a Ca2+-sensing receptor on the regulation of cAMP synthesis and/or hydrolysis. In order to study the regulation of cAMP levels elicited by potentially similar or different mechanisms of action, we compared the effect of extracellular Ca2+ to those of two agents also active in this segment. The first agent, angiotensin II, induces [Ca2+]i increases in the rat CTAL (11, 18). The pattern of the responses observed demonstrates that a same intracellular Ca2+ pool is released by angiotensin II and extracellular Ca2+ (11). The second agent, prostaglandin E2 (PGE2), inhibits hormone-dependent cAMP synthesis (19) likely as a result of the interaction of the PGE2 receptor with a GTP-dependent, pertussis toxin-sensitive Galpha i protein as demonstrated in the medullary portion of the rat thick ascending limb (20).

The experiments were performed on rat CTAL isolated by microdissection, and the results establish that PGE2 (coupled to pertussis toxin-sensitive Galpha i protein), angiotensin II, and extracellular Ca2+ (both coupled to phospholipase C pathway) are effective in a same cell to decrease arginine vasopressin-dependent cAMP accumulation. [Ca2+]e, in the physiological range, decreases hormone-dependent cAMP accumulation by more than 50%, an effect which results from both an inhibition of cAMP synthesis and an increase of cAMP hydrolysis. Angiotensin II also regulates both mechanisms, but its ability to inhibit cAMP synthesis is much smaller. The adenylyl cyclase present in this segment has the functional properties previously described for the Ca2+-inhibitable type 6 AC (21, 22); in particular, AC activity is inhibited by both Galpha i and phospholipase C pathways by different mechanisms. Accordingly, in situ hybridization shows a homogeneous distribution of type 6 AC mRNA in CTAL cells. Taken together, the results establish that the co-expression of a Ca2+ sensing receptor and of a Ca2+-inhibitable AC in the rat CTAL cell allows a specific inhibition by physiological [Ca2+]e of hormone-stimulated cAMP intracellular content.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Unless otherwise specified, the compounds were from Merck (Damstardt, Germany), Sigma, and Calbiochem.

In Situ Hybridization-- A probe specific of type 6 AC was chosen in the most divergent region of AC cDNA sequences. A 376-bp fragment (PvuII-SphI, nucleotides 3766-4143) of the type 6 AC cDNA, located in the 3'-untranslated region, was subcloned in pGEM3Zf(+) in the corresponding sites (SmaI-SphI). This sequence was included in the region previously used for RT-PCR experiments (14). A 1080-bp fragment corresponding to nucleotides 1205 (EcoRI) to 2285 (PvuII) of the type 5 AC cDNA coding region was subcloned in BSSK+. Sense and antisense cRNA probes were transcribed in vitro with T3, T7, or SP6 RNA polymerase (Promega Biotech, Madison, WI) according to the manufacturer's instructions, in the presence of alpha -35S-UTP (>3,000 Ci/mmol, Amersham Pharmacia Biotech, Les Ulis, France).

Adult rat kidneys were fixed by perfusion with 4% paraformaldehyde in phosphate-buffered saline. Kidney slices were post-fixed overnight in the same solution and then dehydrated with graded series of ethanol and butanol. Tissues were paraffin-embedded, and sections of 5-7 µm were mounted on silane-coated slides. In situ hybridization was performed as described by Shanmugam et al. (23). Briefly, slides were deparaffinized in toluene and then rehydrated by a graded series of ethanol (100 to 30%). Pretreatment was continued by boiling in a solution of 0.01 M citric acid in a microwave oven and then treated with 0.1% H2O2 in phosphate-buffered saline. These modifications have been shown to increase specific signal. After a second run of fixation in 4% paraformaldehyde-phosphate-buffered saline, and a proteinase K treatment, slides were covered with hybridization buffer (50% formamide, 21% dextran sulfate (50%), 11% salmon sperm DNA, 11% 20× SSC (1× SSC is equal to 0.15 M NaCl and 0.015 M sodium citrate), and 7% 1 M dithiothreitol) containing 0.5 to 1.106 cpm of probe per tissue section. Hybridization was performed overnight at 50 °C in a humidified chamber. Slides were rinsed in 5× SSC, 10 mM dithiothreitol followed by an incubation in 50% formamide, 1× SSC, 12.5 mM dithiothreitol. They were further treated by RNase A (20 µg/ml) and then dehydrated in ethanol containing 300 mM ammonium acetate and dried. The slides were exposed for 3 to 4 weeks to Kodak NTB2 liquid emulsion, counterstained with Evans blue, and examined under the microscope.

Isolation of Rat Kidney Cortical Thick Ascending Limbs-- The experimental conditions used to perform microdissection of intact segments have been detailed previously (20, 24). Experiments were performed on male Sprague-Dawley rats (120-150 g of body weight, Iffa-Credo, France) that were maintained on a standard diet with free access to water. After anesthesia, the left kidney was perfused with microdissection medium containing 0.16% collagenase (Serva, Boehringer, Mannheim, Germany). After hydrolysis of the kidney (20 min at 30 °C in 0.12% collagenase solution), single CTALs (0.3-1.5 mm length) were microdissected at 4 °C. The standard microdissection medium was composed of the following (in mM): NaCl, 137; KCl, 5; MgSO4, 0.8; Na2HPO4, 0.33; KH2P04, 0.44; MgCl2, 1; NaHCO3, 4; CH3COONa, 10; CaCl2, 0.5; glucose, 5; HEPES, 20, pH 7.4, and 0.1% (w/v) bovine serum albumin (fraction V, protease-free, minimal fatty acid content, Pentex, Miles Inc., Kankakee, IL). This medium was supplemented with 10 µM ibuprofen and 0.5 unit/ml adenosine deaminase (Boehringer Mannheim) to prevent the synthesis of prostaglandins and the release of adenosine, agents known to interact with the regulation of cAMP content in the rat kidney (20, 24). A nominally Ca2+-free medium used in some of our protocols had the same composition except that calcium was omitted; Ca2+-chelating agents were not added to this medium because they have been described to modify the sensitivity to Ca2+ of the Ca2+-inhibitable AC isoforms (25). The concentrations of free Ca2+ present in the media were measured by using an electrode sensitive to Ca2+ (Radiometer, Copenhagen, Denmark). The relationship between the theoretical concentrations of Ca2+ added (0.5-5.0 mM) and those measured in the medium was as follows: y = 1.05x -0.07, r = 1.0.

Measurement of Hormone-dependent cAMP Accumulation-- The experimental conditions used to measure hormone-dependent cAMP accumulation on an intact single segment (20, 24) will be recalled briefly. Microdissected pieces of CTAL were transferred in 2 µl of incubation medium onto glass slides (1 or 2 pieces per slide) and photographed in order to measure their length. Unless otherwise specified, each sample was preincubated for 10 min at 30 °C in 0.5 mM [Ca2+]e and, after addition of 2 µl of incubation medium containing the agonists to be tested, incubated for a further 4 min at 35 °C. Adenylyl cyclase activity was stimulated by arginine vasopressin (AVP) which binds to V2 receptor in the rat CTAL, the only AVP receptor expressed in this segment (26). Due to the small number of cells per tubular sample (from about 100 to 600 cells), hormone-dependent cAMP accumulation can be measured only in the presence of a phosphodiesterase inhibitor. Either 50 µM Ro 20-1724, a specific inhibitor of the low Km cyclic AMP phosphodiesterase (27, 28), or 1 mM IBMX, inhibitor of all phosphodiesterases in the rat kidney (28), was added to the incubation medium. The concentrations of the different agents given in the results are those present during the incubation step. For longer preincubation periods, in experiments performed with Bordetella pertussis toxin and bisindolylmaleimide I, all media were supplemented with essential and nonessential amino acids as well as vitamins (minimum Eagle's medium, Eurobio, Les Ulis, France).

The amounts of cAMP were measured on acetylated samples by radioimmunoassay (Sanofi Diagnostics Pasteur, Marnes-La-Coquette, France). The micromethod used allows the determination of 2-80 fmol of cAMP per reaction tube. In our conditions, the basal level of cyclic AMP present in a single piece of tubule is close to, or below, the sensitivity threshold of the assay (20, 24). The results were calculated in femtomoles of cyclic AMP accumulated per mm of tubular length per 4 min incubation time (fmol·mm-1·4 min-1). The first experiments carried out to study the effect of [Ca2+]e showed that AVP-stimulated cAMP levels were similar either in the Ca2+-free medium or in 0.5 mM [Ca2+]e but decreased in 1 mM [Ca2+]e incubation medium. The control incubation medium therefore contained 0.5 mM [Ca2+]e, a concentration previously used in experiments performed on parathyroid cells (3-5). In each experiment, different experimental conditions were tested on replicate CTAL samples microdissected from a same rat kidney (6-9 samples per condition). The mean of the cAMP values obtained in each condition was taken as one single data point, and the results were expressed in absolute value or in percentage of the response to AVP or in percentage of inhibition calculated from the corresponding AVP value. Results are given as the mean values ± S.E. calculated from n different experiments. Unless otherwise indicated, the statistical evaluation of the data was assessed by unpaired Student's t test.

Measurement of Inositol Phosphate Production-- Assays were performed by using the microtechnique developed for proximal tubule fragments (29) with slight modifications. Briefly, in each experiment, CTAL (150-200 mm of total length) were microdissected from a collagenase-treated kidney. The medium used was supplemented with vitamins and amino acids as described above but contained 2 mM [Ca2+]e. CTAL pieces were radiolabeled in 50 µl of this medium containing myo-[3H]inositol (1 mCi/ml, Amersham Pharmacia Biotech) for 2 h at 30 °C. After this labeling period, tubules were extensively rinsed in 0.5 mM [Ca2+]e medium, and tubule samples (4-7 mm length each) were incubated at 37 °C during 15 min in 0.5 mM [Ca2+]e medium supplemented with lithium. The reaction was stopped, and the radioactivity associated with phosphoinositides, free inositol, inositol phosphates (IP), and glycerophosphoinositol was separated and counted as described previously (29).

In several experiments, it was checked that there was a good correlation between inositol phosphate formation expressed either per unit of tubule length or as a percentage of the total radioactivity counted (r = 0.93 ± 0.03, n = 4), an observation in agreement with that previously observed with proximal tubule fragments (29). Consequently, IP production was expressed as percentage of the total radioactivity counted. In each experiment, different experimental conditions (5 replicate samples each) were tested, and the mean of the IP values measured in each condition was taken as one single data point. The results are given as the mean values ± S.E. calculated from n different experiments. The statistical evaluation of the results was assessed by paired Student's t test.

Measurement of Intracellular Ca2+ Concentration-- Intracellular Ca2+ concentration was measured in single CTAL samples microdissected from collagenase-treated kidneys by using the calcium-sensitive fluorescence probe fura-2 as described previously (11). Briefly, CTAL were loaded for 60 min with 10 µM fura-2 AM. Each CTAL was then transferred to a superfusion chamber fixed on the stage of an inverted fluorescence microscope (Zeiss IM 35, Oberkochen, Germany). The tubule was superfused at 37 °C at a rate of 10-12 ml/min, corresponding to about 10 exchanges per min. The composition of the superfusion medium was similar to that used in cAMP experiments, except that serum albumin, ibuprofen, and adenosine deaminase were not added since the superfusion medium was flushed continuously. After a 5- to 10-min equilibration period, agonists were added to either the 0.5 mM [Ca2+]e medium or to the Ca2+-free medium and superfused over tubule. Due to the dead space of the superfusion set up, the time necessary to achieve a full equilibration of agonist concentration in the chamber was of 15-20 s. The tubular portion selected for fluorescence measurement included about 30 cells. Double wavelength measurements of fura-2 fluorescence were recorded every 2 s.

Calculations of [Ca2+]i were performed as described previously (11). The results obtained from different tubules microdissected from several rats were expressed as mean values ± S.E.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In Situ Hybridization

The localization of type 6 AC mRNA in the rat kidney was examined by in situ hybridization at the light microscope. The most intense labeling in the kidney cortex was found in thick ascending limb, including CTAL (Fig. 1), collecting duct, and glomeruli (not shown). Fig. 1 shows strong labeling of CTALs (a, c, and arrowheads), whereas proximal tubules (a, c, and *) are weakly labeled. In CTAL, labeling was equally intense in all cells. No labeling was observed when the sense cRNA probe was used (Fig. 1, b and d). In contrast to type 6 AC, no significant labeling for type 5 AC was found in CTAL (not shown). This is consistent with previous quantitative RT-PCR results showing that the type 6 AC mRNA was more abundant in CTAL than in proximal tubule and that type 5 AC mRNA was not detected in CTAL (14).


View larger version (155K):
[in this window]
[in a new window]
 
Fig. 1.   In situ hybridization of the Ca2+-inhibitable type 6 AC mRNA. a and b, in indirect fluorescence on Evans blue counterstained kidney sections, CTALs (white arrowheads) are clearly distinguishable from proximal tubules (*). c and d, on the same field in light microscopy, the antisense type 6 AC cRNA (c) strongly labels CTALs (black arrowheads), whereas proximal tubules are weakly labeled (*). No labeling was observed when the sense probe was used (d). Bar = 20 µm.

Effect of Extracellular Ca2+ on AVP-dependent cAMP Content and on the Activation of Phospholipase C

AVP was used at 10 nM, a concentration that induces a maximal stimulation of cAMP accumulation in intact cells (Ref. 19 and data not shown) and thus allows us to study the maximal amount of functional AC proteins present in the rat CTAL.

AVP-dependent cAMP accumulation was about 2-fold higher in the presence of 1 mM IBMX, which reflects AVP-stimulated cAMP synthesis only, than in the presence of 50 µM Ro 20-1724, which allows the measurement of cAMP accumulation that integrates both the synthesis and a partial catabolism of cAMP (Fig. 2, left panel).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of [Ca2+]e increases on AVP-dependent cAMP accumulation in the cortical thick ascending limb. The results are the mean values ± S.E. calculated from different experiments performed in the presence of either 1 mM IBMX (n = 4 experiments) or 50 µM Ro 20-1724 (n = 3). Left panel, mean absolute values of cAMP accumulation induced by 10 nM AVP in CTAL incubated in 0.5 mM [Ca2+]e. *, p < 0.001 when compared with the value obtained with IBMX. Right panel, different [Ca2+]e values were tested in each experiment, and the cAMP values obtained were calculated as the percentage of the corresponding response induced by 10 nM AVP in 0.5 mM [Ca2+]e. [Ca2+]e indicated on the figure are the final concentrations present during the incubation. From 1.5 to 2.5 mM [Ca2+]e, the percentages of responses to AVP obtained in the presence of Ro 20-1724 were significantly lower than the corresponding percentages obtained in the presence of IBMX (p < 0.005 to 0.001).

In the presence of increasing [Ca2+]e, there was a dose-dependent inhibition of AVP-dependent cAMP levels with half-maximal inhibition of about 1.2 and 2.0 mM [Ca2+]e in the presence of Ro 20-1724 and IBMX, respectively (Fig. 2, right panel). With Ro 20-1724, a steep inverse relationship was observed, and thus a small variation of [Ca2+]e induced a high variation of hormone-dependent cAMP accumulation. The shape of the curve obtained with either IBMX or Ro 20-1724 shows that [Ca2+]e below 1.5 mM had a small effect on cAMP synthesis but increased cAMP hydrolysis; conversely, at higher [Ca2+]e the inhibition was mediated mainly by a decrease of cAMP synthesis.

Altogether in this study, the inhibition induced by 1.25 mM [Ca2+]e in the presence of Ro 20-1724 was of 63.3 ± 3.9% (p < 0.001 versus 10 nM AVP, n = 11) and that induced by 1.5 mM [Ca2+]e in the presence of IBMX was of 30.5 ± 3.5% (p < 0.01 versus 10 nM AVP, n = 8).

The implication of the Ca2+ receptor RaKCaR to explain the inhibitory effect of [Ca2+]e was supported by the results obtained with an agonist of this receptor, neomycin (1, 2). In 0.5 mM [Ca2+]e, 100 µM neomycin inhibited by 82.2 ± 5.8% (n = 3) and 43.5 ± 5.7% (n = 5) cAMP accumulated by 10 nM AVP in the presence of Ro 20-1724 and IBMX, respectively.

In the presence of IBMX, 2.5 mM [Ca2+]e inhibited cAMP synthesis stimulated by either 10 µM forskolin or 10 nM AVP with a comparable efficiency (62.3 ± 7.2% of inhibition and 73.5 ± 2.5% in forskolin and AVP experimental groups, respectively, n = 3). These results suggest that [Ca2+]e inhibited AC activity at post-receptor sites.

In our experimental conditions, no detectable [Ca2+]i variations were obtained with 1.25 mM [Ca2+]e (Table I), and the response to 1.5 mM [Ca2+]e was characterized in most tubules by a low but sustained [Ca2+]i increase without a clear-cut peak phase (Fig. 3 and Table I). With 2.5 mM [Ca2+]e, the response was a transient peak followed by a lower sustained plateau (Fig. 3) that reflects Ca2+ entry (11). The simultaneous superfusion of 10 nM AVP and [Ca2+]e did not modify [Ca2+]i variations (data not shown). Unlike the peak, the plateau was blocked by nonspecific Ca2+ channel blockers such as La3+ and Ni2+, whereas addition of voltage-sensitive channel blockers, i.e. verapamil and nifedipine, did not modify [Ca2+]i (Ref. 11 and data not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Effect of agonists on inositol phosphates (IPs) production and on [Ca2+]i in the CTAL
Agonist-induced IPs production was calculated as the stimulated over basal value measured in 0.5 mM [Ca2+]e. Data are the mean values ± S.E. calculated from the indicated number of experiments (n). The data obtained with 1.25 and 1.5 mM [Ca2+]e were obtained in the same experiments. The basal mean value calculated as the percentage of the total radioactivity incorporated in the samples (see "Experimental Procedures") was of 0.09 ± 0.01%, n = 12. 


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3.   [Ca2+]i variations induced by different agonists in the cortical thick ascending limb. Representative traces of [Ca2+]i variations elicited by adding 0.3 µM prostaglandin E2 (PGE2) or 0.1 µM angiotensin II (Angio II) to the 0.5 mM [Ca2+]e control medium or by increasing [Ca2+]e. The superfusion period for each agent is indicated by the bar. Left panel, 1.5 and 2.5 mM Ca2+ are the final concentrations achieved in the superfusion medium. Right panel, note the lack of effect of PGE2 as compared with the high [Ca2+]i increase induced by angiotensin II in the same tubule and the different patterns of [Ca2+]i variations induced by angiotensin II and 2.5 mM [Ca2+]e.

These [Ca2+]i variations were due, at least in part, to phospholipase C activation since increasing [Ca2+]e elicited a dose-dependent production of IPs (Table I). A significant stimulation was observed with 1.25 mM [Ca2+]e, although this concentration had no detectable effect on [Ca2+]i. This apparent discrepancy is probably linked to the following two methodological reasons: (i) discrete and local [Ca2+]i variations may not have been detected in fura-2-loaded CTAL; (ii) a small stimulation of IP production is amplified by the 15-min duration of the incubation performed in the presence of lithium, which results in IP accumulation, whereas [Ca2+]i changes are transient.

Comparison of the Effects of the Ca2+ Receptor and Others Agonists to Decrease AVP-dependent cAMP Accumulation

Angiotensin II and PGE2 were used at concentrations inducing maximal effects (18, 19), and in most experiments, their regulatory properties were studied in parallel to those of [Ca2+]e.

As expected from previous observations (11, 18), 0.1 µM angiotensin II increased IP production and [Ca2+]i (Fig. 3 and Table I). The pattern of [Ca2+]i variations was characterized by a single peak with no apparent plateau phase and thus was different from the response observed with [Ca2+]e. By contrast, 0.3 µM PGE2 did not increase [Ca2+]i or IP production (Fig. 3 and Table I).

Action on cAMP Synthesis and/or on cAMP Hydrolysis-- Fig. 4A shows the mean inhibitions obtained in the presence of either Ro 20-1724 or IBMX. In these two conditions, 0.3 µM PGE2 elicited an inhibition of about 60%, which suggests that PGE2-mediated inhibition was due only to a decrease of cAMP synthesis in the CTAL. In the presence of Ro 20-1724, the inhibition induced by angiotensin II was of smaller extent than that obtained with 2.5 mM [Ca2+]e (Fig. 4A). The use of IBMX instead of Ro 20-1724 decreased angiotensin II-mediated inhibition by more than 50% (p < 0.001 versus Ro 20-1724) and also reduced, but more slightly, the inhibitory effect of 2.5 mM [Ca2+]e (p < 0.005 versus Ro 20-1724). Therefore, although both 2.5 mM [Ca2+]e and angiotensin II induced high [Ca2+]i peak values (Fig. 3), the inhibition of AVP-dependent cAMP synthesis was much more pronounced with the addition of [Ca2+]e.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of phosphodiesterase inhibitors on the inhibition of AVP-dependent cAMP accumulation induced by different agents. A, in each experiment (N), tubule samples microdissected in 0.5 mM [Ca2+]e control medium were incubated in the presence of either 50 µM Ro 20-1724 (open columns) or 1 mM IBMX (hatched columns); the mean cAMP content obtained with the addition of each agent was calculated as the percentage of inhibition of the corresponding response to 10 nM AVP. Data are the mean values ± S.E. calculated from the different experiments. *, p < 0.01; **, p < 0.001 refer to the absolute mean value obtained with each agent compared with the corresponding mean value measured with AVP alone. PGE2 was tested at 0.3 µM and angiotensin II at 0.1 µM; 2.5 mM [Ca2+]e was the final concentration present during the incubation step. B, in each experiment presented in A, the cAMP hydrolysis elicited by Ro 20-1724-insensitive PDEs was calculated by the difference of inhibition between the data obtained in Ro 20-1724- and IBMX-incubated tubules. The same value was calculated from the paired data obtained with 1.5 mM [Ca2+]e in an additional experimental series (see "Results"). The data are the mean values ± S.E. calculated from the different experiments.

The difference between the inhibitions observed with Ro 20-1724 and IBMX reflected the cAMP hydrolysis due to PDE families insensitive to Ro 20-1724 (Fig. 4B). For comparison, the same cAMP hydrolysis value was calculated from the paired data obtained with 1.5 mM [Ca2+] in an additional experimental series. When compared with AVP, 1.5 mM [Ca2+]e induced 73.0 ± 1.7% of inhibition, p < 0.001, and 35.0 ± 3.9%, p < 0.005, in the presence of Ro 20-1724 and IBMX, respectively, n = 5. PDEs insensitive to Ro 20-1724 had a similar efficiency to decrease AVP-dependent cAMP accumulation in angiotensin II- and 2.5 mM [Ca2+]e-incubated CTAL, and this effect was higher with 1.5 mM [Ca2+]e (Fig. 4B). However, this hydrolysis of cAMP due to PDEs insensitive to Ro 20-1724 represented 59.1, 52.2, and 32% with angiotensin II, 1.5 and 2.5 mM [Ca2+]e, respectively, of the total inhibition observed in the presence of Ro 20-1724. Therefore the proportion of inhibition of cAMP accumulation due to cAMP hydrolysis alone was more pronounced with angiotensin II and 1.5 mM [Ca2+]e, in agreement with the data presented in Fig. 2. The addition to the media of 8-methoxymethyl-IBMX, an inhibitor of the Ca2+/calmodulin-dependent PDEs (27), decreased angiotensin II- and extracellular Ca2+-mediated inhibitions (Table II) leading to values comparable to those observed with the use of IBMX (Figs. 2 and 4A). The Ca2+/calmodulin-dependent family therefore appeared as the major PDEs responsible for the cAMP hydrolysis obtained in the presence of Ro 20-1724. 

                              
View this table:
[in this window]
[in a new window]
 
Table II
Effect of an inhibitor of the Ca2+/calmodulin-dependent PDEs on [Ca2+]e- or angiotensin II-mediated inhibition of AVP-dependent cAMP accumulation
In each experiment, tubule samples were preincubated and incubated in 0.5 mM [Ca2+]e and in the presence of either 50 µM Ro 20-1724 (control) or Ro 20-1724 + 75 µM 8-methoxymethyl-IBMX. The effect of [Ca2+]e or angiotensin II was expressed in percentage of inhibition calculated from the corresponding response to 10 nM AVP; 8-methoxymethyl-IBMX increased AVP-dependent cAMP accumulation by about 14%. The data are the mean values calculated from different experiments (n).

Since angiotensin II and [Ca2+]e stimulate phospholipase C, the inhibitions observed could result either directly from this activation or from an effect of enzymes secondarily activated by the phospholipase C pathway. Several attempts were made with the phospholipase C inhibitor U 73122. When used at concentrations that blocked both basal and agonist-dependent IP production, 5 or 7.5 µM, U 73122 alone elicited a high, sustained, and irreversible increase of [Ca2+]i in CTAL (data not shown) and thus was not applicable in our experiments. Bisindolylmaleimide I and 4-bromophenacyl bromide, which inhibit protein kinase C and phospholipase A2 activity, respectively, affected neither AVP-dependent cAMP accumulation nor [Ca2+]e- or angiotensin II-mediated inhibition (Table III). Similarly, 17-octadecynoic acid, an inhibitor of the cytochrome P-450 monooxygenase previously reported to reverse high [Ca2+]e-induced inhibition of apical K+ channels in the CTAL (30), was ineffective on the inhibitions observed (Table III).

                              
View this table:
[in this window]
[in a new window]
 
Table III
Effect of inhibitors of protein kinase C or phospholipase A2 pathways on [Ca2+]e- or angiotensin II-mediated inhibition of AVP-dependent cAMP accumulation
In each experiment, tubule samples were microdissected from the same rat kidney and then preincubated and incubated with Ro 20-1724 in the presence or absence (control) of one of the inhibitors. 4-Bromophenacyl bromide, 17-octadecynoic acid, and bisindolylmaleimide I inhibit phospholipase A2, cytochrome P450 monooxygenase, and protein kinase C, respectively. The effect of [Ca2+]e or angiotensin II was expressed in percentage of inhibition calculated from the corresponding response obtained with 10 nM AVP. The duration of the preincubation period of the samples was of 10 min for all inhibitors except for bisindolylmaleimide I (30 min). The AVP mean value obtained with each inhibitor was not statistically different from the corresponding control AVP mean value. The table gives the mean values ± S.E. calculated from different experiments (n).

Interaction with the GTP-dependent Galpha i Protein-- When expressed in Xenopus oocytes (1), the Ca2+ receptor BoPCaR1 stimulates IP production by a process sensitive to pertussis toxin (PTX). The possible role of a GTP-dependent pertussis toxin-sensitive G protein in the inhibitions observed was studied in CTAL preincubated with 500 ng/ml PTX. When compared with the corresponding responses obtained with 10 nM AVP alone, PGE2-induced inhibition was of 63.4 ± 3.2% (p < 0.001) in control CTAL and was decreased to 28.4 ± 3.4% (p < 0.05 when compared with AVP) in PTX-treated CTAL (Fig. 5). A preincubation with PTX therefore suppressed by more than 50% the inhibition elicited by PGE2, a result identical to that observed in the medullary portion of this segment and due very likely to the interaction of the PGE2 receptor with Galpha i proteins (20). In contrast, angiotensin II- and 2.5 mM [Ca2+]e-mediated inhibition measured in the same experiments were not modified by PTX (Fig. 5).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of pertussis toxin on PGE2-, angiotensin II-, and 2.5 mM [Ca2+]e-mediated inhibition of AVP-dependent cAMP accumulation. In each experiment, tubule samples were microdissected from the same kidney, preincubated (4 h at 35 °C), and incubated (4 min at 35 °C) with or without pertussis toxin (PTX, 500 ng/ml); the effect of each agent was calculated as the percentage of inhibition of the corresponding response to 10 nM AVP. Data are the mean values ± S.E. calculated from 4 experiments performed in the presence of 50 µM Ro 20-1724. p < 0.001 refers to the effect of PTX on PGE2-mediated inhibition; NS indicates that the difference was not significant. *, p < 0.05; **, p < 0.01 or 0.001 when compared with the corresponding mean value obtained with AVP. AVP-stimulated cAMP accumulation was increased in PTX-treated groups (94.2 ± 8.0 fmol·mm-1·4 min-1 and 51.4 ± 2.7 with or without PTX, respectively, p < 0.005).

Experiments of Multiple Combined Inhibition-- The results presented above indicate that only PGE2-mediated inhibition was sensitive to pertussis toxin (Fig. 5), whereas both PGE2 and 2.5 mM [Ca2+]e inhibited AVP-dependent cAMP synthesis with the same efficiency (Fig. 4A). These results suggest that the two agents inhibit cAMP synthesis by two different mechanisms. In order to confirm this hypothesis, and to examine whether these two effects occurred or not in the same cell, we performed experiments of multiple combined inhibition in the presence of IBMX. Experimental conditions and criteria previously defined (24) were used to test a possible summation of inhibitions (if in different cells) or cumulative inhibition (if different mechanisms in a same cell) of AC activity. The residual cAMP content observed with the simultaneous addition of PGE2 and [Ca2+]e was lower than the value obtained with each inhibitor alone, but the response to AVP was not fully abolished although inhibitions higher than 50% were obtained with each agent alone (Table IV). This result indicates that PGE2 and extracellular Ca2+ were active in a same cell. Analysis of the results showed that the measured cAMP value (11.5 ± 3.3 fmol·mm-1·4 min-1, Table IV) was not different from the theoretical cAMP content calculated by assuming an hypothesis of different mechanisms leading to a cumulative inhibition (13.1 ± 4.0 fmol·mm-1·4 min-1). These results and those obtained in pertussis toxin-treated tubules (Fig. 5) demonstrate that PGE2 and [Ca2+]e inhibited AVP-dependent AC activity by different and independent mechanisms effective on a same pool of catalytic units.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Cumulative inhibition of AVP-stimulated cAMP production by 2.5 mM [Ca2+]e and PGE2
In each experiment performed in the presence of 1 mM IBMX, PGE2 and 2.5 mM [Ca2+]e were used alone and in combination in the presence of 10 nM AVP. The percentage of inhibition was calculated from the corresponding response obtained with AVP. Data are the mean values ± S.E. calculated from five experiments.

Combined inhibition experiments were also performed with PGE2 and angiotensin II but in the presence of Ro 20-1724 to compare inhibitions of about the same range. The inhibition obtained with the simultaneous addition of both agents (58.6 ± 8.4% of inhibition, n = 4) was higher than the inhibition induced by angiotensin II added alone (37.7 ± 4.3%) but was in a range comparable to that obtained with PGE2 (48.8 ± 3.3%) and did not represent a full summation of inhibitions. PGE2 and angiotensin II therefore inhibited a same pool of intracellular cAMP. A more thorough analysis of the results was not possible because angiotensin II-induced inhibition resulted from an effect on both cAMP synthesis and cAMP hydrolysis, and the relative part of each process was not known in these experiments.

Role of Intracellular Ca2+ Release and/or Capacitive Ca2+ Influx to Inhibit cAMP Synthesis

The results presented above establish that the decrease of AVP-dependent cAMP accumulation induced by [Ca2+]e or angiotensin II results partly from an inhibition of cAMP synthesis. [Ca2+]e induced both cytosolic Ca2+ release from intracellular stores and extracellular Ca2+ influx (Ref. 11, Table I). Different approaches were used in the presence of IBMX to assess the relative importance of these respective [Ca2+]i variations in the inhibition of cAMP synthesis.

The potential inhibitory effect of the capacitive Ca2+ influx was investigated by the use of thapsigargin. This inhibitor of the endoplasmic reticular Ca2+-ATPase (31) depletes intracellular Ca2+ stores which was shown to produce capacitive Ca2+ entry (32). Thapsigargin added into the Ca2+-free medium evoked a transient [Ca2+]i rise which declined slowly to basal value reflecting Ca2+ release from intracellular stores and Ca2+ extrusion from the CTAL cell (Fig. 6A, lower part). On thapsigargin-treated CTAL, the addition of 200 µM neomycin did not evoke further [Ca2+]i increase indicating that 1 µM thapsigargin had actually emptied intracellular Ca2+ stores sensitive to Ca2+ receptor in the CTAL (data not shown). By contrast, the addition of 1.25 mM [Ca2+]e elicited high [Ca2+]i increases (Fig. 6A, lower part) which reflect a capacitive Ca2+ influx associated to the large emptying of intracellular Ca2+ pools induced by thapsigargin. Without thapsigargin, the addition of 1.25 mM [Ca2+]e to Ca2+-free medium induced only a small and progressive elevation of [Ca2+]i (Fig. 6A, upper part). This discrete increase likely reflects a slow Ca2+ entry consecutive to partial depletion of intracellular Ca2+ stores induced by superfusion in the Ca2+-free medium.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of 1.25 mM [Ca2+]e on [Ca2+]i and AVP-dependent cAMP accumulation in thapsigargin-treated or untreated CTAL. A, examples of [Ca2+]i variations induced by a 10-min superfusion with the Ca2+-free medium followed by the addition of 1.25 mM [Ca2+]e in control (upper part) or thapsigargin-treated CTAL (lower part). In control CTAL, 1.25 mM [Ca2+]e induced a mean [Ca2+]i increase of 35 ± 4 nM after 4 min of superfusion (7 tubules microdissected from 3 kidneys). In thapsigargin-treated CTAL, 1.25 mM [Ca2+]e induced mean [Ca2+]i increases of 83 ± 9 nM after 4 min of superfusion (5 tubules microdissected from 4 kidneys). B, AVP-dependent cAMP accumulation in the presence of IBMX. In each experiment, CTAL samples were microdissected in 0.5 mM [Ca2+]e medium and then extensively rinsed at 4 °C and preincubated (10 min at 30 °C) in the Ca2+-free medium with or without 1 µM thapsigargin. The incubation (4 min at 35 °C) was initiated by the addition of 10 nM AVP in the presence or absence of 1.25 mM [Ca2+]e. Data are the absolute mean values ± S.E. calculated from 4 experiments. *, p < 0.05 versus the corresponding AVP mean value.

The consequences on cAMP synthesis of the changes in [Ca2+]i elicited by the addition of 1.25 mM [Ca2+]e were studied in parallel experiments on CTAL preincubated in the Ca2+-free medium with or without thapsigargin. AVP-stimulated cAMP value was of the same magnitude in both cases (139.6 ± 12.9 fmol·mm-1·4 min-1 and 157.9 ± 13.3, n = 4, without and with thapsigargin, respectively), which indicates that thapsigargin-induced intracellular Ca2+ release during the preincubation step had no inhibitory effect on cAMP synthesized during the following incubation step. AVP-dependent cAMP synthesis was significantly inhibited by 1.25 mM [Ca2+]e in CTAL treated with thapsigargin (mean value of 24.1 ± 1.9% of inhibition, p < 0.05, n = 4), whereas there was no inhibition in the absence of thapsigargin (Fig. 6B). In three of these experiments, the addition of 2.5 mM [Ca2+]e on CTAL treated with thapsigargin inhibited cAMP synthesis by 69.1 ± 2.0%, a value similar to that observed in control CTAL (see Figs. 2 and 4).

The potential inhibition of cAMP synthesis induced only by Ca2+ release from intracellular pools was studied in the Ca2+-free medium with the Ca2+-sensing receptor agonist neomycin to avoid Ca2+ influx associated with [Ca2+]e. Neomycin was added after 10 min superfusion or preincubation of CTAL samples in either the 0.5 mM [Ca2+]e control medium or the Ca2+-free medium. In control medium, neomycin induced [Ca2+]i responses similar to those observed with [Ca2+]e but with a low plateau phase (Fig. 7A compared with Fig. 3). The mean [Ca2+]i peak values were dose-dependent (Fig. 7B), an observation in agreement with the effect of neomycin on IP production; the mean stimulation factor of phospholipase C activity was 2.1 ± 0.3 (n = 4 experiments), 4.7 ± 0.3 (n = 3), and 10.0 ± 2.0 (n = 3) with 100, 200, and 400 µM neomycin, respectively. In Ca2+-free medium, neomycin-induced [Ca2+]i peak values were decreased at all the concentrations tested (Fig. 7B), and the plateau phase was not observed (Fig. 7A).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of neomycin on [Ca2+]i variations and on AVP-dependent cAMP accumulation in a Ca2+-free medium. A, representative traces of [Ca2+]i variations induced by 200 µM neomycin added in either 0.5 mM [Ca2+]e (control) or after a 10-min superfusion with the Ca2+-free medium. Note that neomycin did not evoke the plateau phase in the Ca2+-free medium. B, mean [Ca2+]i increases over basal value observed at the peak with different concentrations of neomycin in either the control (10-15 CTAL from 4 to 8 kidneys) or the Ca2+-free medium (8-13 CTAL from 5 to 6 kidneys). C, neomycin-induced inhibition of AVP-dependent cAMP accumulation in 0.5 mM [Ca2+]e and Ca2+-free medium. In each experiment, CTALs were microdissected from the same rat kidney in 0.5 mM [Ca2+]e medium; some of them were extensively rinsed, then preincubated (10 min at 30 °C), and incubated (4 min at 35 °C) in the Ca2+-free medium; the value obtained in the presence of neomycin was calculated as the percentage of inhibition of the corresponding AVP value. Data are the mean values ± S.E. calculated from 5 (100 µM neomycin) or 4 (200 and 400 µM neomycin) experiments performed in the presence of 1 mM IBMX. *, p < 0.025; **, p < 0.001 versus the corresponding mean value with 10 nM AVP.

Fig. 7C shows the consequence on AVP-dependent cAMP synthesis of neomycin-evoked intracellular Ca2+ release. In the Ca2+-free medium, 100 µM neomycin did not impair cAMP synthesis in contrast to 200 and 400 µM. The mean data (Fig. 7C) indicate that the levels of inhibition obtained in the Ca2+-free medium (37.7 ± 3.4% of inhibition and 67.3 ± 4.7% with 200 and 400 µM neomycin, respectively) were decreased when compared with the corresponding values obtained in the 0.5 mM [Ca2+]e (64.9 ± 3.4% of inhibition and 79.5 ± 1.9% with 200 and 400 µM, respectively).

The lower inhibitions of cAMP obtained in the Ca2+-free medium could be due to the absence of Ca2+ influx and/or to the decrease of intracellular Ca2+ release (Fig. 7). In the absence of extracellular Ca2+, this last effect may be secondary to partial emptying of intracellular Ca2+ stores or to an alteration of the binding of neomycin to the Ca2+ receptor. Additional experiments were performed in CTAL superfused or preincubated in a Ca2+-free medium for only 2 min to prevent the emptying of intracellular Ca2+ stores. In such conditions, 200 µM neomycin evoked intracellular [Ca2+]i peaks of magnitude (418 ± 52 nM, Fig. 8) similar to that observed in 0.5 mM [Ca2+]e medium (436 ± 47 nM, Fig. 7B). With a same experimental timing, the inhibition of cAMP production was 59.9 ± 3.7% (Fig. 8), a value close to that obtained in control medium (64.9 ± 3.4%, Fig. 7C). The similarity of the responses observed in Ca2+-free medium and control medium indicates that the binding of neomycin is not affected by the absence of extracellular Ca2+. Moreover, these results establish that neomycin-evoked intracellular Ca2+ release alone can induce an inhibition of cAMP synthesis comparable to that obtained in 0.5 mM [Ca2+]e medium, a condition in which neomycin induces only a small Ca2+ entry (Fig. 7A). By comparison, angiotensin II elicited high [Ca2+]i peak values in CTAL superfused for 2 min in the Ca2+-free medium (603 ± 104 nM, Fig. 8), and its inhibitory effect on cAMP synthesis was in the range of that obtained with angiotensin II in 0.5 mM [Ca2+]e medium (Fig. 4) with a mean value of only 14.4 ± 2.8% (Fig. 8). Altogether these results therefore support the hypothesis of a specific role played by the activation of the Ca2+ receptor in the inhibition of AVP-dependent cAMP synthesis.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of neomycin and angiotensin II on [Ca2+]i variations and AVP-dependent cAMP accumulation after 2 min in Ca2+-free medium. The left panel gives the mean [Ca2+]i increase over basal value induced by angiotensin II and neomycin. CTAL were superfused with 0.5 mM [Ca2+]e and then in the Ca2+-free medium for 2 min before the addition of the agonist. The shapes of [Ca2+]i variations were identical to those previously shown with neomycin in the Ca2+-free medium (Fig. 7) and angiotensin II in the 0.5 mM [Ca2+]e control medium (Fig. 3). For each agonist, data are the mean values ± S.E. obtained from 6 tubules microdissected from 4 kidneys. The right panel shows the regulation of AVP-dependent cAMP accumulation measured in the presence of 1 mM IBMX. In each experiment, CTALs were microdissected in 0.5 mM [Ca2+]e medium, extensively rinsed for 2 min in the Ca2+-free medium, and immediately incubated; the inhibitory effect of angiotensin II or neomycin was calculated as the percentage of inhibition of the response to 10 nM AVP. Data are the mean values ± S.E. calculated from 5 experiments for angiotensin II and from 4 of them for neomycin. *, p < 0.05; **, p < 0.001 versus the corresponding AVP mean value.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

This study demonstrates that in a same epithelial cell of the rat renal tubule PGE2, angiotensin II and the activation of the Ca2+ receptor inhibit the same pool of AVP-dependent intracellular cAMP content by different mechanisms, i.e. Galpha i-mediated or Ca2+-mediated inhibition of AC activity and PDE-mediated hydrolysis of cAMP. In particular, the strong and specific inhibition of hormone-dependent cAMP synthesis by [Ca2+]e in the CTAL likely results from the co-expression of the Ca2+ receptor RaKCaR (8, 9, 11) and of the Ca2+-inhibitable type 6 AC (Ref. 14 and this study).

Transduction Pathways Involved in PGE2-, Angiotensin II-, and [Ca2+]e-mediated Inhibition of cAMP Content-- Previous studies have established that PGE2 decreases AVP-mediated cAMP synthesis in the rat thick ascending limb (19, 20). The preincubation of isolated segments with PTX reverses, at least partly, this inhibition in medullary (20) and cortical (Fig. 5) segments. The PGE2 receptor is therefore coupled to Galpha i proteins in the thick ascending limb, in agreement with the presence of the PGE2 receptor EP3 subtype (33) usually associated with the inhibition of AC activity (34). Multiple isoforms of the EP3 subtype have been described, some of which coupled to both Galpha i-mediated inhibition of AC activity and activation of phospholipase C (35). In our experiments, PGE2 did not increase IP production or [Ca2+]i (Table I). In addition, the magnitude of PGE2-mediated inhibition did not depend on the type of phosphodiesterase inhibitor added to the incubation medium. Thus, very likely, the coupling of PGE2 receptor to Galpha i-mediated inhibition of AC activity alone accounts for the effect of PGE2 observed on cAMP synthesis in the rat CTAL.

Angiotensin II and [Ca2+]e stimulate phospholipase C activity (Table I and Fig. 3), in agreement with the expected signaling pathway. Indeed, type 1 angiotensin II receptor mRNA is present in the rat CTAL (18, 36) and, when expressed in different cell types, it activates phospholipase C through the PTX-insensitive Gq protein (37, 38). [Ca2+]e increases the production of IPs in parathyroid cells (3, 4). This production is insensitive to PTX (3) and appears to be the direct transduction pathway in parathyroid and human parathyroid Ca2+ receptor-transfected cells (4). A similar transduction pathway has been observed in oocytes expressing the rat renal Ca2+-sensing receptor or the bovine parathyroid Ca2+-sensing receptor (1, 2), but, in these experiments, the IP production was impaired by PTX (1). However, as observed with other receptors expressed in oocytes (39), this sensitivity to PTX may be due to the coupling of the Ca2+ receptor to G proteins other than those expressed in native cells. In CTAL, [Ca2+]e and angiotensin II decrease AVP-dependent cAMP accumulation by a process insensitive to pertussis toxin (Fig. 5) and independent from activation of phospholipase A2, cytochrome P-450 monooxygenase, or protein kinase C (Table III). These results suggest that the inhibition of cAMP accumulation that we observed is a direct consequence of the activation of phospholipase C through a PTX-insensitive G protein. In contrast to our results, PTX reverses the [Ca2+]e-mediated inhibition of hormone-dependent cAMP synthesis in parathyroid cells (5) or mouse medullary thick ascending limbs (40). Several observations may help understanding these different results. First, as underlined by Brown (6), regulation of hormone-dependent cAMP synthesis in parathyroid cells has pharmacological properties that are different from those observed on IP production, thus suggesting the presence of different isoforms of Ca2+ receptor coupled to different G proteins. Second, in some cell types, including bovine parathyroid cells (4), [Ca2+]e increases result in an additional coupling to another pathway such as phospholipase A2-induced arachidonic acid formation which in turn may inhibit AC activity through a PTX-sensitive process as was observed in the rat thick ascending limb (20). Finally, the cell present in the cortical portion of the thick ascending limb is morphologically different from the one described in the medullary portion (17) and exhibits specific physiological functions (10); thus, different cellular properties and/or species differences may explain the discrepant result observed with PTX in the mouse medullary thick ascending limb (40) and the rat cortical thick ascending limb (Fig. 5).

Taken together, our results lead to the conclusion that the negative regulation of the AVP-dependent cAMP accumulation in the rat CTAL involves two different transduction pathways, a PTX-sensitive Galpha i-mediated inhibition of AC activity induced by PGE2 and a PTX-insensitive phospholipase C activation induced by angiotensin II and the activation of the Ca2+ receptor. In addition, results obtained in experiments of multiple combined inhibition demonstrate that the three agents studied are active in a same cell and that PGE2 and [Ca2+]e decrease the same pool of AC catalytic units. These results are in agreement with the observations that only one pool of hormone-stimulable catalytic units is present in the CTAL (15, 16) and that a same intracellular pool of Ca2+ is released by angiotensin II and extracellular Ca2+ (11). Since type 6 AC mRNA is observed in all cells along CTAL (Fig. 1), the functional results obtained suggest that these regulations are effective in a cell which expresses the type 6 AC mRNA.

Mechanisms of Inhibition Induced by Angiotensin II and [Ca2+]e on AVP-dependent cAMP Accumulation-- Different mechanisms account for the inhibition of AVP-dependent cAMP accumulation induced by [Ca2+]e, depending on the Ca2+ concentration studied. Low [Ca2+]e, below 1.5 mM, and angiotensin II used at maximal concentration elicit a modest inhibition of cAMP synthesis (Figs. 2 and 4). These inhibitions are in the range of those previously observed with agonist-evoked phospholipase C activation in cell lines that express type 6 AC (41, 42). Angiotensin II and low [Ca2+]e also induce an hydrolysis of cAMP likely mediated by Ca2+/calmodulin-dependent PDEs. The data from Fig. 2 suggest that regulation of cAMP hydrolysis has a higher sensitivity to Ca2+ than regulation of cAMP synthesis, and thus the hydrolysis of cAMP appears to be the major process that accounts for the decrease of AVP-dependent cAMP accumulation (Figs. 2 and 4 and Table II). Therefore, the small inhibitory effect on cAMP synthesis induced by 1.25 mM [Ca2+]e or angiotensin II is amplified by the cAMP hydrolysis leading to a total inhibition of AVP-dependent cAMP accumulation of about 50% (Figs. 2 and 4 and Table II).

From about 1.5 mM, [Ca2+]e induces a higher inhibition of AVP-dependent cAMP accumulation due to an additional decrease of cAMP synthesis, an effect becoming dominant with high [Ca2+]e (Fig. 2). Previous experiments in the mouse medullary thick ascending limb have established that the inhibitory effect of 5.0 mM [Ca2+]e on hormone-dependent cAMP synthesis is not due to metabolic or cellular damages (43). These observations support the hypothesis that, even at high concentrations, the effect of [Ca2+]e is actually a regulating process.

Although both angiotensin II and [Ca2+]e stimulate phospholipase C pathway in the CTAL, the relative effects of these agents on cAMP synthesis suggest that [Ca2+]e elicits an additional and specific mechanism of action. As will be discussed in the following sections, this specific action of [Ca2+]e might be linked to the co-expression of a functional Ca2+-inhibitable AC and of a Ca2+-sensing receptor in the CTAL cell.

Functional Characteristics of the Adenylyl Cyclase Expressed in the Cortical Thick Ascending Limb-- Among the different isoforms of adenylyl cyclase known up to date, types 4-6 sequences have been cloned from rat tissues and are expressed in the kidney (21). The type 9 AC cloned from mouse cell lines or tissues (44, 45) appears also expressed in the rat kidney (46). Experiments of quantitative RT-PCR have demonstrated the expression of the Ca2+-inhibitable type 6 AC mRNA in the CTAL but not types 4 or 5 AC mRNA (14). Our in situ hybridization results establish that type 6 AC mRNA was expressed in all cells along CTAL (Fig. 1), whereas type 5 AC mRNA was not detected. If present in epithelial cells, the localization of type 9 AC mRNA along the rat renal tubule is not known.

Several properties of regulation of AVP-dependent cAMP accumulation were observed in this study as follows. (i) [Ca2+]e has an inhibitory effect on either hormone- or forskolin-stimulated cAMP production. (ii) cAMP synthesis is inhibited by agents coupled either to an activation of phospholipase C or to a Galpha i protein-mediated process. (iii) These two pathways induce a cumulative inhibition of cAMP synthesis and therefore are effective by independent and different processes on the same pool of catalytic units. (iv) Experimental conditions inducing capacitive Ca2+ entry elicit an inhibition of cAMP synthesis with [Ca2+]e as low as 1.25 mM. (v) There is no evidence of regulation by protein kinase C of either hormone-dependent cAMP synthesis or angiotensin II- and [Ca2+]e-mediated inhibitions. (vi) Finally, the inhibition of cAMP accumulation observed with angiotensin II and low concentrations of [Ca2+]e results from both a modest inhibition of cAMP synthesis and an increase of cAMP hydrolysis.

All these functional properties are in close agreement with those described in different cell lines that express type 6 AC (22), in particular the inhibitory effect of a capacitive Ca2+ entry on cAMP synthesis (42), a [Ca2+]e-mediated inhibition of cAMP synthesis that is cumulative to a Galpha i-mediated pathway (47), and a combined effect of Ca2+ on both AC inhibition and PDE activation in the regulation of cAMP content (41, 42). The type 9 AC is not decreased directly by Ca2+ (45), but its activity is inhibited by [Ca2+]i increases through the activation of the Ca2+/calmodulin-regulated protein phosphatase calcineurin (44). This isoform therefore may be involved in the regulations observed. However, the following two observations suggest that this isoform is unlikely expressed in the rat CTAL. (i) In the AtT20 cell line, from which type 9 AC has been cloned and in which it represents the majority (>90%) of the adenylyl cyclase-related sequences (44), the blockade of calcineurin activity regulates hormone- but not forskolin-stimulated cAMP synthesis (44, 48); by contrast, Ca2+-induced inhibition is obtained on both responses in the CTAL (see "Results") and in cell lines that express type 6 AC (47, 49). (ii) In the AtT20 cell line, the activation of protein kinase C inhibits the synthesis of cAMP (50); by contrast, there is no evidence of interaction with protein kinase C in the rat CTAL (Table III) in agreement with the properties observed with type 6 AC (22).

The different results obtained and their comparison with the data from the literature allow us to conclude that type 6 AC is functionally expressed in the CTAL cell. This Ca2+-inhibitable isoform therefore is the best candidate to account for the inhibitory effect of [Ca2+]e observed in this study.

Specific Inhibition of cAMP Synthesis by Extracellular Ca2+-- As already underlined, both [Ca2+]e and angiotensin II activate the phospholipase C pathway in the same cell but have different consequences on the parameters studied. Indeed, for a comparable magnitude of inhibition of cAMP synthesis (15-20%, Fig. 2 and 4), a high [Ca2+]i peak was observed with angiotensin II, whereas no detectable [Ca2+]i variations were obtained with 1.25 mM [Ca2+]e in our experimental conditions (Table I). Conversely, for comparable [Ca2+]i peak values, activation of the Ca2+ receptor, but not angiotensin II, induced about 60% of inhibition of cAMP synthesis (Fig. 8). We also observed in the rat CTAL that a maximal concentration of bradykinin has properties similar to those of angiotensin II on [Ca2+]i variations and inhibition of cAMP accumulation (data not shown). These results support the hypothesis of a specific role of Ca2+ receptor activation in the inhibition of cAMP synthesis.

By contrast to angiotensin II, [Ca2+]e and the Ca2+ receptor agonist, neomycin, elicit a sustained increase of [Ca2+]i which reflects an entry of Ca2+ (Ref. 11 and Figs. 3 and 7). An activation of cation channels by neomycin has been observed in Ca2+ receptor transfected cells (51), and such an effect in CTAL cell could account, at least in part, for this Ca2+ influx. The entry of Ca2+ might partly explain the properties of [Ca2+]e in the inhibition of cAMP synthesis since (i) previous experiments have demonstrated that capacitive Ca2+ influx inhibits type 6 AC activity in a glioma cell line (42), and (ii) in the present study, a high inhibition of cAMP synthesis can be obtained in thapsigargin-treated CTAL. However, the experiments with neomycin in Ca2+-free medium (Figs. 7 and 8) establish that a release of Ca2+ from intracellular stores can also induce a high inhibition of cAMP synthesis. Therefore, the presence of a Ca2+ influx, on its own, does not totally explain the specific inhibition of cAMP synthesis induced by the activation of the Ca2+ receptor.

The differential inhibitory effect observed with angiotensin II and [Ca2+]e might be linked to the activation of another transduction pathway by one of these agents, and we have no formal argument to support or exclude such an hypothesis. The specific properties observed with the activation of the Ca2+ receptor recalled above lead, however, to another hypothesis supported by observations made in other polarized epithelial cells (52, 53). Indeed in the renal line of Madin-Darby canine kidney cells, inositol 1,4,5-triphosphate receptors have multiple cellular localization including sites close to the basolateral plasma membrane and can thus generate localized [Ca2+]i increases (52). In nasal epithelial cell preparations, phospholipase C activation results in [Ca2+]i release and Ca2+ influx in close proximity to the stimulated receptor (53). These data might explain the high efficiency of cAMP synthesis inhibition by [Ca2+]e if the Ca2+ receptor was more closely associated to type 6 AC than the angiotensin II receptor in the CTAL plasma membrane.

An intimate co-localization in a subdomain of the basal membrane of the Ca2+ receptor and of the Ca2+-inhibitable AC might also explain the similar inhibition of cAMP synthesis observed with either a local [Ca2+]i increase (Ca2+ influx and/or Ca2+ release) elicited by low [Ca2+]e or a high intracellular Ca2+ release induced by angiotensin II. In addition, the cAMP hydrolysis observed with low [Ca2+]e or angiotensin II was similar (Table II), suggesting that a local [Ca2+]i increase must be effective to activate Ca2+/calmodulin-dependent PDEs. These hypotheses cannot be tested on isolated tubule samples at the present time.

Whatever the precise mechanism involved, the co-expression of the Ca2+-inhibitable type 6 AC and of the Ca2+-sensing receptor RaKCaR in the plasma membrane very likely allows the specific inhibition of AC activity observed with [Ca2+]e. This conclusion is supported by previous results obtained in the vasopressin-sensitive cell of the rat outer medullary collecting tubule (14). In this cell type, different data support the functional expression of the type 6 AC, but [Ca2+]e increases do not inhibit cAMP synthesis (14). In contrast to the CTAL, there is no evidence for the presence of the Ca2+ receptor RaKCaR in the plasma membrane of the medullary collecting tubule (8, 9). The co-expression (CTAL) or the absence of co-expression (vasopressin-sensitive cell of the outer medullary collecting tubule) of the type 6 AC and of the Ca2+ receptor RaKCaR may explain, therefore, the different effect of [Ca2+]e on AC activity observed in these segments.

From a physiological point of view, the inhibition of AC activity in the CTAL cell, together with an effect on cAMP hydrolysis, confers a high sensitivity to [Ca2+]e on the inhibition of hormone-stimulated cAMP accumulation. The steep slope (Fig. 2) obtained shows that a large variation of cAMP content is elicited by a small change in [Ca2+]e. It is noticeable that a same slope has been observed in parathyroid cells, and 1.0-1.2 mM [Ca2+]e defined as the "set point" of parathyroid hormone secretion, i.e. the concentration at which hormonal secretion is inhibited by 50% (6). Similarly in the kidney, the present data show that inhibition of hormone-stimulated cAMP accumulation is exquisitely sensitive to variations in [Ca2+]e that are physiologically relevant thus allowing the modulation of cAMP-mediated luminal Ca2+ reabsorption usually present in the CTAL (10). At higher [Ca2+]e, like in hypercalcemia (6, 7), the strong inhibition of cAMP synthesis may be a potent factor to decrease sharply hormone-dependent cAMP content and thus to block Ca2+ reabsorption. Our functional data support that the co-expression of a Ca2+-inhibitable AC and of a Ca2+-sensing receptor in the plasma membrane of the CTAL cell contributes to the regulation of one of its main physiological functions.

    ACKNOWLEDGEMENTS

We are grateful to N. Griffiths and A. Doucet for critical advice and careful review of this manuscript; to J. M. Gasc for helpful suggestions to develop the in situ hybridization technique; to R. Rajerison and M. Bloch-Faure for their valuable advice in the development of phosphoinositide assay; and to H. Moysan and S. David for helpful technical assistance.

    Note Added in Proof

While this manuscript was being typeset, results describing an inhibitory effect of [Ca2+]e increases on chloride reabsorption in rat CTAL have been accepted for publication (M. C. de Jesus Ferreira and C. Bailly, Am. J. Physiol., in press).

    FOOTNOTES

* This work was supported in part by Grant URA 1859 from the Centre National de la Recherche Scientifique and from the CEA (DBCM, SBCe).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by a doctoral fellowship from the Ministère de l'Education Nationale, de la Recherche et de la Technologie.

§ Supported by a postdoctoral fellowship from the Commissariat à l'Energie Atomique.

To whom correspondence should be addressed: DBCM, SBCe, Bât. 520, CEA Saclay, 91191 Gif sur Yvette, France. Tel.: 33 (0)1 69 08 97 61; Fax: 33 (0)1 69 08 35 70; E-mail: chabardes{at}dsvidf.cea.fr.

1 The abbreviations used are: [Ca2+]e, extracellular free concentration of Ca2+; AC, adenylyl cyclase; AVP, arginine vasopressin; [Ca2+]i, intracellular free concentration of Ca2+; CTAL, cortical portion of the thick ascending limb; IBMX, 3-isobutyl-1-methylxanthine; IP, inositol phosphates; PDE, phosphodiesterase; PGE2, prostaglandin E2; PTX, Bordetella pertussis toxin; RT-PCR, reverse transcription-polymerase chain reaction; Ro 20-1724, 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Brown, E. M., Gamba, G., Riccardi, D., Lombardi, M., Butters, R., Kifor, O., Sun, A., Hediger, M. A., Lytton, J., and Hebert, S. C. (1993) Nature 366, 575-580[CrossRef][Medline] [Order article via Infotrieve]
  2. Riccardi, D., Park, J., Lee, W.-S., Gamba, G., Brown, E. M., and Hebert, S. C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 131-135[Abstract]
  3. Hawkins, D., Enyedi, P., and Brown, E. (1989) Endocrinology 124, 838-844[Abstract]
  4. Kifor, O., Diaz, R., Butters, R., and Brown, E. M. (1997) J. Bone Miner. Res. 12, 715-725[Medline] [Order article via Infotrieve]
  5. Chen, C. J., Barnett, J. V., Congo, D. A., and Brown, E. M. (1989) Endocrinology 124, 233-239[Abstract]
  6. Brown, E. M. (1991) Physiol. Rev. 71, 371-411[Free Full Text]
  7. Brown, E. M., and Hebert, S. C. (1997) Bone (NY) 20, 303-309[CrossRef][Medline] [Order article via Infotrieve]
  8. Riccardi, D., Lee, W.-S., Lee, K., Segre, G. V., Brown, E. M., and Hebert, S. C. (1996) Am. J. Physiol. 271, F951-F956[Abstract/Free Full Text]
  9. Yang, T., Hassan, S., Huang, Y. G., Smart, A. M., Briggs, J. P., and Schnermann, J. B. (1997) Am. J. Physiol. 272, F751-F758[Abstract/Free Full Text]
  10. Morel, F., and Doucet, A. (1986) Physiol. Rev. 66, 377-468[Free Full Text]
  11. Champigneulle, A., Siga, E., Vassent, G., and Imbert-Teboul, M. (1997) J. Membr. Biol. 156, 117-129[CrossRef][Medline] [Order article via Infotrieve]
  12. Paulais, M., Baudoin-Legros, M., and Teulon, J. (1996) Am. J. Physiol. 271, F1052-F1060[Abstract/Free Full Text]
  13. Takaichi, K., and Kurokawa, K. (1986) Miner. Electrolyte Metab. 12, 342-346[Medline] [Order article via Infotrieve]
  14. Chabardès, D., Firsov, D., Aarab, L., Clabecq, A., Bellanger, A. C., Siaume-Perez, S., and Elalouf, J. M. (1996) J. Biol. Chem. 271, 19264-19271[Abstract/Free Full Text]
  15. Morel, F., Chabardès, D., Imbert-Teboul, M., Le Bouffant, F., Hus-Citharel, A., and Montégut, M. (1982) Kidney Int. 21, S55-S62
  16. Morel, F., Imbert-Teboul, M., and Chabardès, D. (1987) Kidney Int. 31, 512-520[Medline] [Order article via Infotrieve]
  17. Kriz, W., and Kaissling, B. (1992) in The Kidney: Physiology and Pathophysiology (Seldin, D. W., and Giebisch, G., eds), 2nd Ed., pp. 707-777, Raven Press, Ltd., New York
  18. Bouby, N., Hus-Citharel, A., Marchetti, J., Bankir, L., Corvol, P., and Llorens-Cortes, C. (1997) J. Am. Soc. Nephrol. 8, 1658-1667[Abstract]
  19. Torikai, S., and Kurokawa, K. (1983) Am. J. Physiol. 245, F58-F66[Medline] [Order article via Infotrieve]
  20. Firsov, D., Aarab, L., Mandon, B., Siaume-Perez, S., de Rouffignac, C., and Chabardès, D. (1995) Pfluegers Arch. 429, 636-646[Medline] [Order article via Infotrieve]
  21. Iyengar, R. (1993) FASEB J. 7, 768-775[Abstract/Free Full Text]
  22. Cooper, D. M. F., Mons, N., and Fagan, K. (1994) Cell. Signalling 6, 823-840[Medline] [Order article via Infotrieve]
  23. Shanmugam, S., Llorens-Cortes, C., Clauser, E., Corvol, P., and Gasc, J. M. (1995) Am. J. Physiol. 268, F922-F930[Abstract/Free Full Text]
  24. Aarab, L., Montégut, M., Siaume-Perez, S., Imbert-Teboul, M., and Chabardès, D. (1993) Pfluegers Arch. 423, 397-405[Medline] [Order article via Infotrieve]
  25. Smith, J. A., Griffin, M., Mireylees, S. E., and Long, R. G. (1993) FEBS Lett. 327, 137-140[CrossRef][Medline] [Order article via Infotrieve]
  26. Firsov, D., Mandon, B., Morel, A., Merot, J., Le Maout, S., Bellanger, A. C., de Rouffignac, C., Elalouf, J. M., and Buhler, J. M. (1994) Pfluegers Arch. 429, 79-89[Medline] [Order article via Infotrieve]
  27. Beavo, J. A. (1995) Physiol. Rev. 75, 725-748[Abstract/Free Full Text]
  28. Hoey, M., and Houslay, M. D. (1990) Biochem. Pharmacol. 40, 193-202[Medline] [Order article via Infotrieve]
  29. Meneton, P., Imbert-Teboul, M., Bloch-Faure, M., and Rajerison, R. M. (1996) Am. J. Physiol. 271, F382-F390[Abstract/Free Full Text]
  30. Wang, W.-H., Lu, M., and Hebert, S. C. (1996) Am. J. Physiol. 271, C103-C111[Abstract/Free Full Text]
  31. Thastrup, O., Cullen, P. J., Drobak, B. K., Hanley, M. R., and Dawson, A. P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2466-2470[Abstract]
  32. Putney, J. W., Jr. (1990) Cell Calcium 11, 611-624[Medline] [Order article via Infotrieve]
  33. Takeuchi, K., Abe, T., Takahashi, N., and Abe, K. (1993) Biochem. Biophys. Res. Commun. 194, 885-891[CrossRef][Medline] [Order article via Infotrieve]
  34. Sugimoto, Y., Namba, T., Honda, A., Hayashi, Y., Negishi, M., Ichikawa, A., and Narumiya, S. (1992) J. Biol. Chem. 267, 6463-6466[Abstract/Free Full Text]
  35. Namba, T., Sugimoto, Y., Negishi, M., Irie, A., Ushikubi, F., Kakizuka, A., Ito, S., Ichikawa, A., and Narumiya, S. (1993) Nature 365, 166-170[CrossRef][Medline] [Order article via Infotrieve]
  36. Abe, T., Takeuchi, K., Takahashi, N., Tsutsumi, E., Taniyama, Y., and Abe, K. (1995) J. Clin. Invest. 96, 657-664[Medline] [Order article via Infotrieve]
  37. Murphy, T. J., Alexander, R. W., Griendling, K. K., Runge, M. S., and Bernstein, K. E. (1991) Nature 351, 233-236[CrossRef][Medline] [Order article via Infotrieve]
  38. Wang, C., Jayadev, S., and Escobedo, J. A. (1995) J. Biol. Chem. 270, 16677-16682[Abstract/Free Full Text]
  39. Moriarty, T. M., Sealfon, S. C., Carty, D. J., Roberts, J. L., Iyengar, R., and Landau, E. M. (1989) J. Biol. Chem. 264, 13524-13530[Abstract/Free Full Text]
  40. Takaichi, K., and Kurokawa, K. (1988) J. Clin. Invest. 82, 1437-1444[Medline] [Order article via Infotrieve]
  41. Stevens, T., Nakahashi, Y., Cornfield, D. N., McMurtry, I. F., Cooper, D. M. F., and Rodman, D. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2696-2700[Abstract]
  42. Chiono, M., Mahey, R., Tate, G., and Cooper, D. M. F. (1995) J. Biol. Chem. 270, 1149-1155[Abstract/Free Full Text]
  43. Takaichi, K., Uchida, S., and Kurokawa, K. (1986) Am. J. Physiol. 250, F770-F776[Abstract/Free Full Text]
  44. Antoni, F. A., Barnard, R. J. O., Shipston, M. J., Smith, S. M., Simpson, J., and Paterson, J. M. (1995) J. Biol. Chem. 270, 28055-28061[Abstract/Free Full Text]
  45. Premont, R. T., Matsukoa, I., Mattei, M.-G., Pouille, Y., Defer, N., and Hanoune, J. (1996) J. Biol. Chem. 271, 13900-13907[Abstract/Free Full Text]
  46. Shen, T., Suzuki, Y., Poyard, M., Miyamoto, N., Defer, N., and Hanoune, J. (1997) Am. J. Physiol. 273, C323-C330[Abstract/Free Full Text]
  47. Boyajian, C. L., Garritsen, A., and Cooper, D. M. F. (1991) J. Biol. Chem. 266, 4995-5003[Abstract/Free Full Text]
  48. Koch, B., and Lutz-Bucher, B. (1994) Cell. Signalling 6, 467-473[Medline] [Order article via Infotrieve]
  49. DeBernardi, M. A., Munshi, R., and Brooker, G. (1993) Mol. Pharmacol. 43, 451-458[Abstract]
  50. Kock, B., and Lutz-Bucher, B. (1993) Mol. Cell. Endocrinol. 92, 175-181[CrossRef][Medline] [Order article via Infotrieve]
  51. Ye, C., Rogers, K., Bai, M., Quinn, S. J., Brown, E. M., and Vassilev, P. M. (1996) Biochem. Biophys. Res. Commun. 226, 572-579[CrossRef][Medline] [Order article via Infotrieve]
  52. Bush, K. T., Stuart, R. O., Li, S.-H., Moura, L. A., Sharp, A. H., Ross, C. A., and Nigam, S. K. (1994) J. Biol. Chem. 269, 23694-23699[Abstract/Free Full Text]
  53. Paradiso, A. M., Mason, S. J., Lazarowski, E. R., and Boucher, R. C. (1995) Nature 377, 643-646[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.